91 related articles for article (PubMed ID: 12647593)
1. [Effects of nicotine and cannabinoids on the central nervous system].
Seutin V
Rev Med Liege; 2003 Jan; 58(1):19-21. PubMed ID: 12647593
[TBL] [Abstract][Full Text] [Related]
2. The involvement of accumbal glycine receptors in the dopamine-elevating effects of addictive drugs.
Jonsson S; Adermark L; Ericson M; Söderpalm B
Neuropharmacology; 2014 Jul; 82():69-75. PubMed ID: 24686030
[TBL] [Abstract][Full Text] [Related]
3. Nicotine pre-exposure does not potentiate the locomotor or rewarding effects of Delta-9-tetrahydrocannabinol in rats.
Le Foll B; Wiggins M; Goldberg SR
Behav Pharmacol; 2006 Mar; 17(2):195-9. PubMed ID: 16495727
[TBL] [Abstract][Full Text] [Related]
4. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.
Valjent E; Mitchell JM; Besson MJ; Caboche J; Maldonado R
Br J Pharmacol; 2002 Jan; 135(2):564-78. PubMed ID: 11815392
[TBL] [Abstract][Full Text] [Related]
5. The neurobiology and evolution of cannabinoid signalling.
Elphick MR; Egertová M
Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
[TBL] [Abstract][Full Text] [Related]
6. Cannabis: pharmacology and toxicology in animals and humans.
Adams IB; Martin BR
Addiction; 1996 Nov; 91(11):1585-614. PubMed ID: 8972919
[TBL] [Abstract][Full Text] [Related]
7. The endocannabinoid system and the brain.
Mechoulam R; Parker LA
Annu Rev Psychol; 2013; 64():21-47. PubMed ID: 22804774
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors.
Kobayashi H; Suzuki T; Kamata R; Saito S; Sato I; Tsuda S; Matsusaka N
J Toxicol Sci; 1999 Feb; 24(1):1-16. PubMed ID: 10073332
[TBL] [Abstract][Full Text] [Related]
9. [Neurobiology of endocannabinoids and central effects of tetrahydrocannabinol contained in indian hemp].
Costentin J
Bull Acad Natl Med; 2014 Mar; 198(3):527-38; discussion 538-9. PubMed ID: 26427295
[TBL] [Abstract][Full Text] [Related]
10. Mouse cerebellar nicotinic-cholinergic receptor modulation of Delta9-THC ataxia: role of the alpha4beta2 subtype.
Smith AD; Dar MS
Brain Res; 2006 Oct; 1115(1):16-25. PubMed ID: 16934231
[TBL] [Abstract][Full Text] [Related]
11. Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.
Scherma M; Muntoni AL; Melis M; Fattore L; Fadda P; Fratta W; Pistis M
Psychopharmacology (Berl); 2016 May; 233(10):1765-77. PubMed ID: 26728894
[TBL] [Abstract][Full Text] [Related]
12. Recognising nicotine: the neurobiological basis of nicotine discrimination.
Smith JW; Stolerman IP
Handb Exp Pharmacol; 2009; (192):295-333. PubMed ID: 19184654
[TBL] [Abstract][Full Text] [Related]
13. Interactions between nicotine and drugs of abuse: a review of preclinical findings.
Kohut SJ
Am J Drug Alcohol Abuse; 2017 Mar; 43(2):155-170. PubMed ID: 27589579
[TBL] [Abstract][Full Text] [Related]
14. Nicotinic receptors and stages of nicotine dependence.
Brennan KA; Lea RA; Fitzmaurice PS; Truman P
J Psychopharmacol; 2010 Jun; 24(6):793-808. PubMed ID: 19251827
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.
Le Foll B; Goldberg SR
J Pharmacol Exp Ther; 2005 Mar; 312(3):875-83. PubMed ID: 15525797
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine.
Picciotto MR; Zoli M; Rimondini R; Léna C; Marubio LM; Pich EM; Fuxe K; Changeux JP
Nature; 1998 Jan; 391(6663):173-7. PubMed ID: 9428762
[TBL] [Abstract][Full Text] [Related]
17. Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.
Crooks PA; Ayers JT; Xu R; Sumithran SP; Grinevich VP; Wilkins LH; Deaciuc AG; Allen DD; Dwoskin LP
Bioorg Med Chem Lett; 2004 Apr; 14(8):1869-74. PubMed ID: 15050618
[TBL] [Abstract][Full Text] [Related]
18. Molecular and cellular mechanisms of action of nicotine in the CNS.
Barik J; Wonnacott S
Handb Exp Pharmacol; 2009; (192):173-207. PubMed ID: 19184650
[TBL] [Abstract][Full Text] [Related]
19. Nicotine and endogenous opioids: neurochemical and pharmacological evidence.
Hadjiconstantinou M; Neff NH
Neuropharmacology; 2011 Jun; 60(7-8):1209-20. PubMed ID: 21108953
[TBL] [Abstract][Full Text] [Related]
20. Cellular approaches to the interaction between cannabinoid receptor ligands and nicotinic acetylcholine receptors.
Oz M; Al Kury L; Keun-Hang SY; Mahgoub M; Galadari S
Eur J Pharmacol; 2014 May; 731():100-5. PubMed ID: 24642359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
